2022 forecast: Pharma has the tools. Will clinical trials be less white in next year?

The data are clear: White patients make up the majority in clinical trials. But the drug development industry--despite a lot of progress and an awareness among the largest pharmas out there--still leaves out many underrepresented populations in clinical testing. [ABSTRACT FROM AUTHOR]Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)